Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Vincenza Conteduca; Anuradha Jayaram; Nuria Romero-Laorden; Daniel Wetterskog; Samanta Salvi; Giorgia Gurioli; Emanuela Scarpi; Elena Castro; Mercedes Marin-Aguilera; Cristian Lolli; Giuseppe Schepisi; Antonio Maugeri; Anna Wingate; Alberto Farolfi; Valentina Casadio; Ana Medina; Javier Puente; Mª José Méndez Vidal; Rafael Morales-Barrera; Jose C. Villa-Guzmán; Susana Hernando; Alejo Rodriguez-Vida; Aránzazu González-del-Alba; Begoña Mellado; Enrique Gonzalez-Billalabeitia; David Olmos; Gerhardt Attard; Ugo De Giorgi

doi:10.1016/j.eururo.2018.09.049

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C. Villa-GuzmánSusana Hernando, Alejo Rodriguez-Vida, Aránzazu González-del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.

Original language	English
Pages (from-to)	368-373
Number of pages	6
Journal	European Urology
Volume	75
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2018.09.049
Publication status	Published - Mar 2019

Keywords

Androgen receptor
Androgen receptor–directed therapies
Biomarker
Castration-resistant prostate cancer
Docetaxel
Plasma DNA

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2018.09.049

Cite this

Conteduca, V., Jayaram, A., Romero-Laorden, N., Wetterskog, D., Salvi, S., Gurioli, G., Scarpi, E., Castro, E., Marin-Aguilera, M., Lolli, C., Schepisi, G., Maugeri, A., Wingate, A., Farolfi, A., Casadio, V., Medina, A., Puente, J., Vidal, M. J. M., Morales-Barrera, R., ... De Giorgi, U. (2019). Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European Urology, 75(3), 368-373. https://doi.org/10.1016/j.eururo.2018.09.049

Conteduca, V, Jayaram, A, Romero-Laorden, N, Wetterskog, D, Salvi, S, Gurioli, G , Scarpi, E, Castro, E, Marin-Aguilera, M, Lolli, C , Schepisi, G, Maugeri, A, Wingate, A, Farolfi, A, Casadio, V, Medina, A, Puente, J, Vidal, MJM, Morales-Barrera, R, Villa-Guzmán, JC, Hernando, S, Rodriguez-Vida, A, González-del-Alba, A, Mellado, B, Gonzalez-Billalabeitia, E, Olmos, D, Attard, G & De Giorgi, U 2019, 'Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer', European Urology, vol. 75, no. 3, pp. 368-373. https://doi.org/10.1016/j.eururo.2018.09.049

@article{ff99bed6efc3454c9213017ddfa488f4,

title = "Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer",

abstract = "Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.",

keywords = "Androgen receptor, Androgen receptor–directed therapies, Biomarker, Castration-resistant prostate cancer, Docetaxel, Plasma DNA",

author = "Vincenza Conteduca and Anuradha Jayaram and Nuria Romero-Laorden and Daniel Wetterskog and Samanta Salvi and Giorgia Gurioli and Emanuela Scarpi and Elena Castro and Mercedes Marin-Aguilera and Cristian Lolli and Giuseppe Schepisi and Antonio Maugeri and Anna Wingate and Alberto Farolfi and Valentina Casadio and Ana Medina and Javier Puente and Vidal, {Mª Jos{\'e} M{\'e}ndez} and Rafael Morales-Barrera and Villa-Guzm{\'a}n, {Jose C.} and Susana Hernando and Alejo Rodriguez-Vida and Ar{\'a}nzazu Gonz{\'a}lez-del-Alba and Bego{\~n}a Mellado and Enrique Gonzalez-Billalabeitia and David Olmos and Gerhardt Attard and {De Giorgi}, Ugo",

year = "2019",

month = mar,

doi = "10.1016/j.eururo.2018.09.049",

language = "English",

volume = "75",

pages = "368--373",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

AU - Conteduca, Vincenza

AU - Jayaram, Anuradha

AU - Romero-Laorden, Nuria

AU - Wetterskog, Daniel

AU - Salvi, Samanta

AU - Gurioli, Giorgia

AU - Scarpi, Emanuela

AU - Castro, Elena

AU - Marin-Aguilera, Mercedes

AU - Lolli, Cristian

AU - Schepisi, Giuseppe

AU - Maugeri, Antonio

AU - Wingate, Anna

AU - Farolfi, Alberto

AU - Casadio, Valentina

AU - Medina, Ana

AU - Puente, Javier

AU - Vidal, Mª José Méndez

AU - Morales-Barrera, Rafael

AU - Villa-Guzmán, Jose C.

AU - Hernando, Susana

AU - Rodriguez-Vida, Alejo

AU - González-del-Alba, Aránzazu

AU - Mellado, Begoña

AU - Gonzalez-Billalabeitia, Enrique

AU - Olmos, David

AU - Attard, Gerhardt

AU - De Giorgi, Ugo

PY - 2019/3

Y1 - 2019/3

N2 - Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.

AB - Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.

KW - Androgen receptor

KW - Androgen receptor–directed therapies

KW - Biomarker

KW - Castration-resistant prostate cancer

KW - Docetaxel

KW - Plasma DNA

UR - http://www.scopus.com/inward/record.url?scp=85055497223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055497223&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.09.049

DO - 10.1016/j.eururo.2018.09.049

M3 - Article

C2 - 30773204

AN - SCOPUS:85055497223

VL - 75

SP - 368

EP - 373

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this